drugset / Trial / NCT00527267
Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Subjects on Hemodialysis will be randomized to AMG 073 or placebo. The screening period is a maximum of 30 days followed by a 26-week treatment period. Lab assessments will be completed throughout the study along with PRO assessments.
Timeline
- Start
- 2002-02
- Primary completion
- 2003-04
- Completion
- 2003-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cinacalcet | Other / unclassified | 30 mg | Oral |
| Subject | Cinacalcet | Other / unclassified | 60 mg | Oral |
| Subject | Cinacalcet | Other / unclassified | 90 mg | Oral |
| Subject | Cinacalcet | Other / unclassified | 120 mg | Oral |
| Subject | Cinacalcet | Other / unclassified | 180 mg | Oral |